Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis

Journal of Gastroenterology

Volumn 48, Issue 6, 2013, Pages 738-750

  Saeki, Issei ^a   Terai, Shuji ^a   Fujisawa, Koichi ^a   Takami, Taro ^a   Yamamoto, Naoki ^a   Matsumoto, Toshihiko ^a   Hirose, Yoshikazu ^a   Murata, Yasuhiko ^a   Yamasaki, Takahiro ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bortezomib; Hepatocellular carcinoma; Liver fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BORTEZOMIB; CYCLIN D1; LACTATE DEHYDROGENASE; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CYTOTOXICITY; ENZYME ASSAY; ENZYME RELEASE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE CELL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL DEATH; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; PYRAZINES; RATS; RATS, WISTAR;

EID: 84879421765     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0675-z     Document Type: Article

References (22)

1. Kamangar F, Dores G, Anderson W. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-50.
2. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. El-Serag H, Marrero J, Rudolph L, Reddy K. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752-63.
4. Sakaida I, Hironaka K, Uchida K, Suzuki C, Kayano K, Okita K. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology. 1998;28:1247-52.
5. Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol. 2005;43:458-64.
6. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993;188:79-83.
7. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer. 2001;91:1342-8.
8. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240:451-9 (discussion 459-61).
9. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
10. Kogure T, Iwasaki T, Ueno Y, Kanno N, Fukushima K, Yamagiwa Y, et al. Complete remission of a case of hepatocellular carcinoma with tumor invasion in inferior vena cava and with pulmonary metastasis successfully treated with repeated arterial infusion chemotherapy. Hepatogastroenterology. 2007;54:2113-6.
11. Nakamura M, Nagano H, Wada H, Noda T, Ota H, Damdinsuren B, et al. A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha. J Gastroenterol. 2006;41:1120-5.
12. Shirahashi H, Sakaida I, Terai S, Hironaka K, Kusano N, Okita K. Ubiquitin is a possible new predictive marker for the recurrence of human hepatocellular carcinoma. Liver. 2002;22:413-8.
13. Chen K, Yu H, Liu T, Lee S, Chen P, Cheng A. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol. 2010;52:88-95.
14. Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, et al. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30:387-94.
15. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology. 2006;43:335-44.
16. Yamamoto N, Wu J, Zhang Y, Catana A, Cai H, Strom S, et al. An optimal culture condition maintains human hepatocyte phenotype after long-term culture. Hepatol Res. 2006;35:169-77.
17. Lappalainen K, Jääskeläinen I, Syrjänen K, Urtti A, Syrjänen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res. 1994;11:1127-31.
18. Takami T, Terai S, Yokoyama Y, Tanimoto H, Tajima K, Uchida K, et al. Human homologue of maid is a useful marker protein in hepatocarcinogenesis. Gastroenterology. 2005;128:1369-80.
19. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun. 2004;315:187-95.
20. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-22.
21. Calvaruso G, Giuliano M, Portanova P, De Blasio A, Vento R, Tesoriere G. Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8. Mol Cell Biochem. 2006;287:13-9.
22. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-6.